AR126987A2 - Inmunoconjugados - Google Patents

Inmunoconjugados

Info

Publication number
AR126987A2
AR126987A2 ARP220102406A ARP220102406A AR126987A2 AR 126987 A2 AR126987 A2 AR 126987A2 AR P220102406 A ARP220102406 A AR P220102406A AR P220102406 A ARP220102406 A AR P220102406A AR 126987 A2 AR126987 A2 AR 126987A2
Authority
AR
Argentina
Prior art keywords
polypeptide
rhv
immunoconjugate
amino acid
acid sequence
Prior art date
Application number
ARP220102406A
Other languages
English (en)
Inventor
Laura Codarri Klein Christian Lauener Laura Nicolini Valeria G Seeber Stefan Umaa Pablo Waldhau Deak
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR126987A2 publication Critical patent/AR126987A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere de manera general a inmunoconjugados, en particular inmunoconjugados que comprenden un polipéptido interleuquina-2 mutante y un anticuerpo que se une a PD-1. Además, la invención se refiere a moléculas de polinucleótido codificantes de los inmunoconjugados y a vectores y células huésped que comprenden dichas moléculas de polinucleótido. La invención se refiere además a métodos para producir los polipéptidos mutantes, a composiciones farmacéuticas que los comprenden y a usos de los mismos. Reivindicación 1: Inmunoconjugado que comprende: (i) un anticuerpo que se une a PD-1 e (ii) un polipéptido que señaliza mediante IL-2Rbg, en particular un polipéptido IL-2 o un polipéptido IL-15, en el que el polipéptido IL-2 es un polipéptido IL-2 mutante, en el que el polipéptido IL-2 mutante es una molécula de IL-2 humana que comprende las sustituciones de aminoácidos F42A, Y45A y L72G (numeración respecto a la secuencia de IL-2 humana SEQ ID Nº 19) y en el que el anticuerpo comprende (a) una región variable de cadena pesada (VH) que comprende una RHV-H1 que comprende la secuencia de aminoácidos SEQ ID Nº 8, una RHV-H2 que comprende la secuencia de aminoácidos SEQ ID Nº 9 y una RHV-H3 que comprende la secuencia de aminoácidos SEQ ID Nº 10 y (b) una región variable de cadena ligera (VL) que comprende una RHV-L1 que comprende la secuencia de aminoácidos SEQ ID Nº 11, una RHV-L2 que comprende la secuencia de aminoácidos SEQ ID Nº 12 y una RHV-L3 que comprende la secuencia de aminoácidos SEQ ID Nº 13. Reivindicación 20: Uno o más polinucleótidos aislados codificantes del inmunoconjugado según cualquiera de las reivindicaciones 1 a 19. Reivindicación 21: Uno o más vectores, particularmente vectores de expresión, que comprenden el polinucleótido o polinucleótidos según la reivindicación 20. Reivindicación 22: Célula huésped que comprende el polinucleótido o polinucleótidos según la reivindicación 20 o el vector o vectores según la reivindicación 21. Reivindicación 23: Método para producir un inmunoconjugado que comprende un polipéptido IL-2 mutante y un anticuerpo que se une a PD-1, que comprende: (a) cultivar la célula huésped según la reivindicación 21 bajo condiciones adecuadas para la expresión del inmunoconjugado y opcionalmente (b) recuperar el inmunoconjugado. Reivindicación 25: Composición farmacéutica que comprende el inmunoconjugado según cualquiera de las reivindicaciones 1 a 19 o 24 y un portador farmacéuticamente aceptable.
ARP220102406A 2017-04-03 2022-09-06 Inmunoconjugados AR126987A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17164533 2017-04-03

Publications (1)

Publication Number Publication Date
AR126987A2 true AR126987A2 (es) 2023-12-06

Family

ID=58488892

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP180100833A AR111400A1 (es) 2017-04-03 2018-04-03 Inmunoconjugados que comprenden un polipéptido il-2 mutante y un anticuerpo que se une a pd-1
ARP220102406A AR126987A2 (es) 2017-04-03 2022-09-06 Inmunoconjugados

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP180100833A AR111400A1 (es) 2017-04-03 2018-04-03 Inmunoconjugados que comprenden un polipéptido il-2 mutante y un anticuerpo que se une a pd-1

Country Status (32)

Country Link
US (2) US11413331B2 (es)
EP (2) EP4201953A1 (es)
JP (3) JP7426825B2 (es)
KR (2) KR20190121816A (es)
CN (2) CN117003887A (es)
AR (2) AR111400A1 (es)
AU (1) AU2018247765B2 (es)
BR (1) BR112019017329A2 (es)
CA (1) CA3053357A1 (es)
CL (1) CL2019002346A1 (es)
CO (1) CO2019009354A2 (es)
CR (1) CR20190426A (es)
DK (1) DK3606946T3 (es)
ES (1) ES2928718T3 (es)
HR (1) HRP20221254T1 (es)
HU (1) HUE059885T2 (es)
IL (1) IL269395B1 (es)
LT (1) LT3606946T (es)
MA (1) MA49033B1 (es)
MX (2) MX2019011770A (es)
MY (1) MY201482A (es)
PE (1) PE20191494A1 (es)
PH (1) PH12019502273A1 (es)
PL (1) PL3606946T3 (es)
PT (1) PT3606946T (es)
RS (1) RS63663B1 (es)
RU (1) RU2761377C2 (es)
SG (1) SG11201909205YA (es)
TW (1) TWI800506B (es)
UA (1) UA125700C2 (es)
WO (1) WO2018184964A1 (es)
ZA (1) ZA201905517B (es)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017055404A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Bispecific antibodies specific for pd1 and tim3
AU2017339856B2 (en) * 2016-10-06 2024-09-05 Merck Patent Gmbh Dosing regimen of avelumab for the treatment of cancer
CA3056630A1 (en) 2017-03-15 2018-09-20 Pandion Therapeutics, Inc. Targeted immunotolerance
CN107082812B (zh) * 2017-03-29 2018-11-13 上海科医联创生物科技有限公司 一种恢复衰竭性免疫细胞功能的融合蛋白及其应用
CN117003887A (zh) 2017-04-03 2023-11-07 豪夫迈·罗氏有限公司 抗pd-1抗体与突变体il-2或与il-15的免疫缀合物
MA49038A (fr) 2017-04-05 2020-02-12 Hoffmann La Roche Anticorps bispécifiques se liant particulièrement à pd1 et lag3
CN111010866A (zh) 2017-05-24 2020-04-14 潘迪恩治疗公司 靶向免疫耐受性
HUE058233T2 (hu) 2017-08-03 2022-07-28 Amgen Inc Interleukin-21-muteinek és kezelési eljárások
MX2020005041A (es) 2017-11-21 2020-10-12 Univ Leland Stanford Junior Agonistas parciales de interleucina-2.
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
EP3737694B1 (en) 2018-01-12 2023-03-01 Amgen Inc. Anti-pd-1 antibodies and methods of treatment
SG11202005873QA (en) 2018-09-17 2020-07-29 Gi Innovation Inc Fusion protein comprising il-2 protein and cd80 protein, and use thereof
JP7496091B2 (ja) * 2018-10-29 2024-06-06 １グローブ バイオメディカル カンパニー， リミテッド 合理的に設計された新規なタンパク質組成物
CA3123338A1 (en) * 2018-12-21 2020-06-25 Ose Immunotherapeutics Bifunctional anti-pd-1/il-7 molecule
US20220025050A1 (en) * 2018-12-21 2022-01-27 Ose Immunotherapeutics Bifunctional molecule directed against human pd-1
CN114679909A (zh) 2019-05-20 2022-06-28 潘迪恩运营公司 MAdCAM靶向的免疫耐受
US20220251202A1 (en) * 2019-06-05 2022-08-11 Asher Biotherapeutics, Inc. Fusions of mutant interleukin-2 polypeptides with antigen binding molecules for modulating immune cell function
CN114008082A (zh) * 2019-06-24 2022-02-01 南京金斯瑞生物科技有限公司 单克隆抗体-细胞因子融合蛋白二聚体及其应用
CN116574183A (zh) * 2019-08-22 2023-08-11 盛禾(中国)生物制药有限公司 多功能抗体、其制备及其用途
CN112679615B (zh) * 2019-10-17 2023-09-22 瑞阳(苏州)生物科技有限公司 一种融合蛋白
WO2021101273A2 (ko) * 2019-11-20 2021-05-27 주식회사 지아이셀 조절 t 세포 배양용 조성물 및 이의 용도
WO2021102063A1 (en) 2019-11-20 2021-05-27 Anwita Biosciences, Inc. Cytokine fusion proteins, and their pharmaceutical compositions and therapeutic applications
MX2022006295A (es) * 2019-11-27 2022-06-08 Gi Cell Inc Composicion para el tratamiento anticancerigeno, que comprende celulas nk y proteina de fusion que comprende la proteina il-2 y la proteina cd80.
EP4072593A4 (en) * 2019-12-13 2024-01-03 Cugene Inc. BIOACTIVABLE CYTOKINE DRUGS AND ASSOCIATED METHODS OF USES
BR112022012112A2 (pt) 2019-12-20 2022-09-06 Regeneron Pharma Agonistas de il2 e métodos de uso dos mesmos
KR20220140514A (ko) 2020-01-10 2022-10-18 브라이트 피크 테라퓨틱스 아게 변형된 il-2 폴리펩타이드 및 그의 용도
KR102559355B1 (ko) * 2020-01-31 2023-07-25 주식회사 제넥신 항-taa 항체, 항-pd-l1 항체 및 il-2를 포함하는 융합단백질 및 이의 용도
CN115135999A (zh) 2020-02-13 2022-09-30 豪夫迈·罗氏有限公司 用于通过核磁共振弛豫法来确定aav颗粒的负载状态的方法
EP4107187A4 (en) 2020-02-21 2024-07-03 Pandion Operations Inc TISSUE-TARGETED IMMUNOTOLERANCE WITH A CD39 EFFECTOR
EP4143329A4 (en) 2020-04-28 2024-10-16 Anwita Biosciences Inc INTERLEUKIN-2 POLYPEPTIDES AND FUSION PROTEINS THEREOF, AS WELL AS THEIR PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC APPLICATIONS
CA3177288A1 (en) 2020-05-11 2021-11-18 F.Hoffmann-La Roche Ag Combination therapy with modified pbmcs and an immunoconjugate
EP4149554A4 (en) 2020-05-13 2024-05-29 Bonum Therapeutics, Inc. COMPOSITIONS OF PROTEIN COMPLEXES AND METHODS OF USE THEREOF
CN115916831A (zh) * 2020-06-30 2023-04-04 Gi 医诺微新 包含抗lag-3抗体和il-2的融合蛋白及其用途
US11865082B2 (en) 2020-09-09 2024-01-09 Hoffmann-La Roche Inc. Combination therapy of PD-1-targeted IL-2 variant immunocytokines and antibodies against human PD-L1
TW202233673A (zh) * 2020-10-23 2022-09-01 美商雅雪生物治療公司 含調節免疫細胞功能之ｃｄ８抗原結合分子之融合物
WO2022098954A1 (en) 2020-11-06 2022-05-12 Nektar Therapeutics Tlr agonist compounds and related cancer immunotherapy methods
WO2022117692A2 (en) 2020-12-04 2022-06-09 F. Hoffmann-La Roche Ag Ph-dependent mutant interleukin-2 polypeptides
WO2022125694A1 (en) * 2020-12-09 2022-06-16 Asher Biotherapeutics, Inc. Fusions of interleukin polypeptides with bispecific antigen binding molecules for modulating immune cell function
IL303809A (en) 2020-12-22 2023-08-01 Neogene Therapeutics B V Peptide markers for tracking genetically engineered cells
CN114712495B (zh) * 2021-01-06 2024-08-20 盛禾(中国)生物制药有限公司 一种多功能抗体的组合物
WO2022148853A1 (en) * 2021-01-11 2022-07-14 F. Hoffmann-La Roche Ag Immunoconjugates
CA3209640A1 (en) 2021-03-09 2022-09-15 F. Hoffmann-La Roche Ag Combination therapy of pd-1-targeted il-2 variant immunoconjugates and fap/4-1bb binding molecules
EP4304724A1 (en) 2021-03-09 2024-01-17 F. Hoffmann-La Roche AG Combination therapy of pd-1-targeted il-2 variant immunoconjugate and anti-tyrp1/anti-cd3 bispecific antibodies
EP4314032A1 (en) 2021-03-30 2024-02-07 F. Hoffmann-La Roche AG Protease-activated polypeptides
KR20240005741A (ko) 2021-04-09 2024-01-12 오제 이뮈노테라프틱스 특성이 향상된 이작용성 분자용 신규한 스캐폴드
TW202317623A (zh) * 2021-06-14 2023-05-01 美商再生元醫藥公司 基於il2之治療劑及其使用方法
MX2023015400A (es) 2021-06-23 2024-03-07 Cytune Pharma Variantes de interleucina 15.
EP4359428A2 (en) 2021-06-23 2024-05-01 Cytune Pharma Interleukin-15 based immunocytokines
CN115521379B (zh) * 2021-07-16 2023-12-22 南京吉盛澳玛生物医药有限公司 Pd-1抗体及其用途
WO2023045977A1 (zh) * 2021-09-22 2023-03-30 信达生物制药(苏州)有限公司 白介素2突变体以及其融合蛋白
CN118019849A (zh) * 2021-09-26 2024-05-10 上海药明生物技术有限公司 Il-2变体及其融合蛋白
AU2022390563A1 (en) * 2021-11-17 2024-05-30 F. Hoffmann-La Roche Ag Compositions of protein complexes and methods of use thereof
KR20240145492A (ko) * 2022-02-11 2024-10-07 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 면역접합체 및 이의 용도
TW202413442A (zh) 2022-06-16 2024-04-01 美商希佛隆有限責任公司 抗pd-1抗體減弱之il-2免疫結合物及其用途
WO2024043643A1 (ko) * 2022-08-23 2024-02-29 머스트바이오 주식회사 Il2 변이체 및 이를 포함하는 단백질 복합체
WO2024068705A1 (en) 2022-09-29 2024-04-04 F. Hoffmann-La Roche Ag Protease-activated polypeptides
CN116041539B (zh) * 2022-10-31 2023-07-21 山东博安生物技术股份有限公司 Il-2突变体免疫缀合物
EP4431525A1 (en) 2023-03-16 2024-09-18 Anaveon AG Il-2 fusion protein
WO2024133825A1 (en) 2022-12-22 2024-06-27 Anaveon AG Anti-pd-1 antibody antigen-binding domain and immunoconjugate
WO2024153725A1 (en) 2023-01-20 2024-07-25 F. Hoffmann-La Roche Ag Recombinant fc domain - il2 variant polypeptides and combination therapy with membrane-anchored antigen binding polypeptides
WO2024165454A1 (en) 2023-02-06 2024-08-15 F. Hoffmann-La Roche Ag Combination therapy and uses thereof
WO2024193670A1 (zh) * 2023-03-21 2024-09-26 弗维塔生物制药（新加坡）有限公司 抗pd-1与突变il-2免疫缀合物制剂
CN118725136A (zh) * 2023-03-21 2024-10-01 上海赛金生物医药有限公司 抗pd-1/抗tigit双特异性抗体与il-2的融合蛋白及应用
WO2024199458A1 (en) * 2023-03-29 2024-10-03 Wuxi Biologics (Shanghai) Co., Ltd. Il-2 variants with improved stability and compositions thereof

Family Cites Families (196)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1156905B (it) 1977-04-18 1987-02-04 Hitachi Metals Ltd Articolo di ornamento atto ad essere fissato mediante un magnete permanente
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US5116943A (en) 1985-01-18 1992-05-26 Cetus Corporation Oxidation-resistant muteins of Il-2 and other protein
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
DE3676670D1 (de) 1985-06-26 1991-02-07 Cetus Corp Solubilisierung von proteinen fuer pharmazeutische zusammensetzungen mittels polymerkonjugierung.
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP2919890B2 (ja) 1988-11-11 1999-07-19 メディカル リサーチ カウンスル 単一ドメインリガンド、そのリガンドからなる受容体、その製造方法、ならびにそのリガンドおよび受容体の使用
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
ATE295420T1 (de) 1992-02-06 2005-05-15 Chiron Corp Marker für krebs und biosynthetisches bindeprotein dafür
US5229109A (en) 1992-04-14 1993-07-20 Board Of Regents, The University Of Texas System Low toxicity interleukin-2 analogues for use in immunotherapy
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6066322A (en) 1995-03-03 2000-05-23 Millennium Pharmaceuticals, Inc. Methods for the treatment of immune disorders
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
IL130168A (en) 1996-11-29 2006-09-05 Serono Lab Genetically engineered cells containing LAG-3-expressing DNA and their use
EP0979281B1 (en) 1997-05-02 2005-07-20 Genentech, Inc. A method for making multispecific antibodies having heteromultimeric and common components
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
IL136544A0 (en) 1997-12-05 2001-06-14 Scripps Research Inst Humanization of murine antibody
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
CN100427603C (zh) 1999-10-04 2008-10-22 麦迪卡格公司 调控外源基因转录的方法
EP1240319A1 (en) 1999-12-15 2002-09-18 Genentech, Inc. Shotgun scanning, a combinatorial method for mapping functional protein epitopes
US20020004587A1 (en) 2000-04-11 2002-01-10 Genentech, Inc. Multivalent antibodies and uses therefor
KR20080074231A (ko) 2000-06-29 2008-08-12 아보트 러보러터리즈 이중 특이성 항체 및 이의 제조 및 사용 방법
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
WO2002043478A2 (en) 2000-11-30 2002-06-06 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
AU2002355955A1 (en) 2001-08-13 2003-03-03 University Of Southern California Interleukin-2 mutants with reduced toxicity
CA2466279A1 (en) 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
DK1454138T3 (da) 2001-12-04 2012-02-13 Merck Patent Gmbh Immunocytokiner med moduleret selektivitet
CA2474497C (en) 2002-01-30 2013-12-03 The Brigham And Women's Hospital, Inc. Compositions and methods related to tim-3, a th1-specific cell surface molecule
AU2003239966B9 (en) 2002-06-03 2010-08-26 Genentech, Inc. Synthetic antibody phage libraries
ES2654064T3 (es) 2002-07-03 2024-03-13 Ono Pharmaceutical Co Composiciones inmunopotenciadoras que comprenden anticuerpos anti-PD-L1
CA2501818C (en) 2002-10-10 2012-03-27 Merck Patent Gesellschaft Mit Beschraenkter Haftung Pharmaceutical compositions directed to erb-b1 receptors
CA2508660C (en) 2002-12-23 2013-08-20 Wyeth Antibodies against pd-1 and uses therefor
AU2004205631A1 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
US7563869B2 (en) 2003-01-23 2009-07-21 Ono Pharmaceutical Co., Ltd. Substance specific to human PD-1
US7772188B2 (en) * 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
RU2005127664A (ru) 2003-02-06 2006-09-10 Микромет Аг (De) Тримерная полипептидная конструкция, индуцирующая пролонгированный т-клеточный ответ
EP1897548B2 (en) 2003-02-28 2024-05-22 The Johns Hopkins University T cell regulation
AU2003272065A1 (en) 2003-04-03 2004-10-25 Yissum Research Development Company Of The Hebrew University Of Jerusalem Broad-spectrum in-vivo effective superantigen toxin antagonists based on the interaction between cd28 and the superantigen and uses thereof
CN1934255B (zh) 2003-08-27 2012-07-11 奥普索特克公司 用于治疗眼新血管疾病的组合治疗
CA2561686C (en) 2004-03-31 2014-12-02 Genentech, Inc. Humanized anti-tgf-beta antibodies
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
PT1737891E (pt) 2004-04-13 2013-04-16 Hoffmann La Roche Anticorpos anti p-selectina
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
RU2412947C2 (ru) 2004-09-23 2011-02-27 Дженентек, Инк. Антитела, сконструированные на основе цистеинов, и их конъюгаты
RS59761B1 (sr) 2005-02-07 2020-02-28 Roche Glycart Ag Antigen vezujući molekuli, koji vezuju egfr, vektori koji kodiraju iste, i njihova upotreba
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
JP4361545B2 (ja) 2005-05-09 2009-11-11 小野薬品工業株式会社 ＰｒｏｇｒａｍｍｅｄＤｅａｔｈ１（ＰＤ−１）に対するヒトモノクローナル抗体および抗ＰＤ−１抗体単独または他の免疫療法と併用した癌治療方法
EP2397155B1 (en) 2005-06-08 2017-12-13 Dana-Farber Cancer Institute, Inc. Methods and compositions for the treatment of persistent infections by inhibiting the programmed cell death 1 (PD-1)pathway
JP2006345852A (ja) 2005-06-16 2006-12-28 Virxsys Corp 抗体複合体
RS54271B1 (en) 2005-07-01 2016-02-29 E. R. Squibb & Sons, L.L.C. HUMAN MONOCLONIC ANTIBODIES FOR LIGAND PROGRAMMED DEATH 1 (PD-L1)
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
WO2007056441A2 (en) 2005-11-07 2007-05-18 Genentech, Inc. Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
JP5102772B2 (ja) 2005-11-29 2012-12-19 ザ・ユニバーシティ・オブ・シドニー デミボディ：二量体化活性化治療剤
EP1973951A2 (en) 2005-12-02 2008-10-01 Genentech, Inc. Binding polypeptides with restricted diversity sequences
AR060070A1 (es) 2006-03-24 2008-05-21 Merck Patent Gmbh Dominios proteicos heterodimericos obtenidos por ingenieria
EP2016101A2 (en) 2006-05-09 2009-01-21 Genentech, Inc. Binding polypeptides with optimized scaffolds
CN105837690A (zh) 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
CN101490085A (zh) 2006-06-12 2009-07-22 特鲁比昂药品公司 具有效应功能的单链多价结合蛋白
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
PT2066796E (pt) 2006-09-20 2011-10-11 Mt Biomethan Gmbh Procedimento e dispositivo para a separação do metano e do dióxido de carbono do biogás
WO2008071447A2 (en) 2006-12-15 2008-06-19 Ablynx N.V. Amino acid sequences that modulate the interaction between cells of the immune system
CA2673870A1 (en) 2006-12-27 2008-07-10 Emory University Compositions and methods for the treatment of infections and tumors
US9244059B2 (en) 2007-04-30 2016-01-26 Immutep Parc Club Orsay Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
WO2009015917A2 (en) 2007-05-14 2009-02-05 F. Hoffmann-La Roche Ag Dihydroquinone and dihydronaphthridine inhibitors of jnk
US8828666B2 (en) 2007-06-18 2014-09-09 Chugai Seiyaku Kabushiki Kaisha Method for measuring bonding activity of antibody which mimics antibody-dependent cell medicated cytotoxic activity
ES2616355T3 (es) 2007-06-18 2017-06-12 Merck Sharp & Dohme B.V. Anticuerpos para el receptor humano de muerte programada PD-1
US20090028857A1 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
US9243052B2 (en) 2007-08-17 2016-01-26 Daniel Olive Method for treating and diagnosing hematologic malignancies
JP2011500730A (ja) 2007-10-26 2011-01-06 ガバニング カウンセル オブ ザ ユニバーシティ オブ トロント Ｔｉｍ−３を用いた治療および診断方法
WO2009061853A2 (en) 2007-11-05 2009-05-14 Massachusetts Institute Of Technology Mutant interleukin-2 (il-2) polypeptides
ES2774337T3 (es) 2008-01-07 2020-07-20 Amgen Inc Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática
AU2009213738B2 (en) 2008-02-11 2015-01-22 Curetech Ltd. Monoclonal antibodies for tumor treatment
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
DK2604693T3 (en) 2008-07-21 2016-05-30 Apogenix Gmbh Single-chain TNFSF molecules
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
EA201500417A1 (ru) 2008-08-25 2015-11-30 Эмплиммьюн, Инк. Композиции антагонистов pd-1 и способы применения
EA201170375A1 (ru) 2008-08-25 2012-03-30 Эмплиммьюн, Инк. Антагонисты pd-1 и способы их применения
US9181342B2 (en) 2008-09-12 2015-11-10 Isis Innovation Limited PD-1 specific antibodies and uses thereof
AU2009290544B2 (en) 2008-09-12 2015-07-16 Oxford University Innovation Limited PD-1 specific antibodies and uses thereof
CA2998281C (en) 2008-09-26 2022-08-16 Dana-Farber Cancer Institute, Inc. Human anti-pd-1 antobodies and uses therefor
KR101721707B1 (ko) 2008-11-28 2017-03-30 에모리 유니버시티 감염 및 종양 치료 방법
WO2010084999A1 (en) 2009-01-26 2010-07-29 Protegene, Inc. Immunosuppressive agents and prophylactic and therapeutic agents for autoimmune diseases
ES2629337T3 (es) 2009-02-09 2017-08-08 Inserm - Institut National De La Santé Et De La Recherche Médicale Anticuerpos contra PD-1 y anticuerpos contra PD-L1 y usos de los mismos
EP2396318A4 (en) 2009-02-11 2013-06-05 Life Technologies Corp COLORANTS WITH HIGH STOKES DERIVATION
CN102369215B (zh) 2009-04-02 2015-01-21 罗切格利卡特公司 包含全长抗体和单链Fab片段的多特异性抗体
AU2010245011B2 (en) 2009-04-27 2015-09-03 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
KR101588598B1 (ko) 2009-08-17 2016-01-29 로슈 글리카트 아게 표적화된 면역접합체
JP2013512251A (ja) 2009-11-24 2013-04-11 アンプリミューン、インコーポレーテッド Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害
AU2010343056A1 (en) 2009-12-29 2012-08-02 Emergent Product Development Seattle, Llc Ron binding constructs and methods of use thereof
DK2542590T4 (da) * 2010-03-05 2020-07-13 Univ Johns Hopkins Sammensætninger og fremgangsmåde til målrettede immunomodulatoriske antistof-fer og fusionproteiner
US8993731B2 (en) 2010-03-11 2015-03-31 Ucb Biopharma Sprl PD-1 antibody
TW201134488A (en) 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
EP2569337A1 (en) 2010-05-14 2013-03-20 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
TR201807750T4 (tr) 2010-06-11 2018-06-21 Kyowa Hakko Kirin Co Ltd Anti-TIM-3 antikoru.
WO2011159877A2 (en) 2010-06-18 2011-12-22 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
CA2806021C (en) 2010-08-13 2019-05-21 Roche Glycart Ag Anti-fap antibodies and methods of use
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
CN105440123B (zh) * 2011-02-10 2020-10-09 罗切格利卡特公司 突变体白介素-2多肽
LT2691417T (lt) 2011-03-29 2018-10-25 Roche Glycart Ag Antikūno fc variantai
CA2831820C (en) 2011-04-01 2021-05-25 Universitat Stuttgart Recombinant tnf ligand family member polypeptides with antibody binding domain and uses thereof
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
WO2013006490A2 (en) 2011-07-01 2013-01-10 Cellerant Therapeutics, Inc. Antibodies that specifically bind to tim3
FR2977674B1 (fr) 2011-07-06 2015-08-14 Cisbio Bioassays Methode amelioree de detection et/ou de quantification d'un analyte present a la surface d'une cellule
EP2543680A1 (en) 2011-07-07 2013-01-09 Centre National de la Recherche Scientifique Multispecific mutated antibody Fab fragments
AU2012288413B2 (en) 2011-07-24 2016-10-13 Curetech Ltd. Variants of humanized immunomodulatory monoclonal antibodies
SG2014012298A (en) 2011-08-11 2014-06-27 Medarex Llc Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
FR2980271B1 (fr) 2011-09-16 2013-10-11 Cisbio Bioassays Procede de determination de la glycosylation d'un anticorps
JP6541974B2 (ja) 2011-12-20 2019-07-10 メディミューン，エルエルシー 二重特異的抗体足場用改変ポリペプチド
BR112014017630A8 (pt) 2012-02-01 2017-07-11 Hoffmann La Roche Métodos para a determinação de presença e/ou da quantidade de um antígeno
PL2814587T3 (pl) 2012-02-15 2018-10-31 F.Hoffmann-La Roche Ag Chromatografia powinowactwa oparta na receptorze Fc
JP5585973B2 (ja) 2012-03-22 2014-09-10 三井造船株式会社 Ｆｒｅｔ計測装置及びｆｒｅｔ計測方法
NZ799532A (en) 2012-04-20 2023-07-28 Merus Nv Methods and means for the production of ig-like molecules
NZ722585A (en) 2012-04-30 2017-03-31 Biocon Ltd Targeted/immunomodulatory fusion proteins and methods for making same
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
SI3495387T1 (sl) 2012-07-13 2021-12-31 Roche Glycart Ag Bispecifična protitelesa proti VEGF/proti ANG-2 in njihova uporaba pri zdravljenju bolezni očesnih žil
CA2872195A1 (en) 2012-08-07 2014-02-13 Roche Glycart Ag Composition comprising two antibodies engineered to have reduced and increased effector function
EP2904093B1 (en) 2012-10-03 2019-04-10 Zymeworks Inc. Methods of quantitating heavy and light chain polypeptide pairs
LT2970464T (lt) 2013-03-15 2020-08-25 Glaxosmithkline Intellectual Property Development Limited Anti-lag-3 surišantys baltymai
PT2992017T (pt) 2013-05-02 2021-01-29 Anaptysbio Inc Anticorpos dirigidos contra a morte programada 1 (pd-1)
EP4269441A3 (en) 2013-08-08 2024-01-24 Cytune Pharma Il-15 and il-15ralpha sushi domain based on modulokines
KR20230008255A (ko) 2013-09-20 2023-01-13 브리스톨-마이어스 스큅 컴퍼니 종양을 치료하기 위한 항-lag-3 항체 및 항-pd-1 항체의 조합물
US10570204B2 (en) 2013-09-26 2020-02-25 The Medical College Of Wisconsin, Inc. Methods for treating hematologic cancers
PT3081576T (pt) 2013-12-12 2019-10-15 Jiangsu Hengrui Medicine Co Anticorpo pd-1, fragmento de ligação ao antigénio do mesmo e aplicação médica do mesmo
CA2934028A1 (en) 2013-12-17 2015-06-25 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
CA2931986A1 (en) 2014-01-15 2015-07-23 F. Hoffmann-La Roche Ag Fc-region variants with modified fcrn- and maintained protein a-binding properties
US10794898B2 (en) 2014-01-17 2020-10-06 Regents Of The University Of Minnesota High-throughput, high-precision methods for detecting protein structural changes in living cells
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
SI3556775T1 (sl) 2014-01-28 2022-02-28 Bristol-Myers Squibb Company Protitelesa proti-LAG-3 za zdravljenje hematoloških malignosti
CN113583129A (zh) 2014-03-14 2021-11-02 诺华股份有限公司 针对lag-3的抗体分子及其用途
UA117289C2 (uk) 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Мультиспецифічне антитіло
JP2017513901A (ja) 2014-04-25 2017-06-01 ジェネンテック， インコーポレイテッド トラスツズマブ−ｍｃｃ−ｄｍ１及びペルツズマブにより早期の乳癌を処置する方法
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
MX2017002426A (es) 2014-08-29 2017-06-20 Hoffmann La Roche Terapia de combinacion de inmunocitocinas variantes de il-2 dirigidas a tumores y anticuerpos contra pd-l1 humana.
WO2016071448A1 (en) 2014-11-06 2016-05-12 F. Hoffmann-La Roche Ag Anti-tim3 antibodies and methods of use
RS61870B1 (sr) 2014-11-14 2021-06-30 Hoffmann La Roche Antigen vezujući molekuli koji sadrže trimer liganda iz tnf familije
ES2926673T3 (es) 2014-11-20 2022-10-27 Hoffmann La Roche Politerapia de moléculas de unión a antígeno biespecíficas activadoras de linfocitos T y antagonistas de la unión al eje de PD-1
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
DK3237446T3 (en) 2014-12-22 2021-07-26 Pd 1 Acquisition Group Llc Anti-PD-1-antistoffer
MA41463A (fr) 2015-02-03 2017-12-12 Anaptysbio Inc Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
EP3064507A1 (en) * 2015-03-06 2016-09-07 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Fusion proteins comprising a binding protein and an interleukin-15 polypeptide having a reduced affinity for IL15ra and therapeutic uses thereof
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
AU2016281641B2 (en) 2015-06-23 2022-01-20 Eureka Therapeutics, Inc. Novel PD-1 immune modulating agents
CN108348601B (zh) 2015-07-22 2022-05-17 索伦托药业有限公司 与lag3结合的抗体治疗剂
EP3344654B1 (en) 2015-09-02 2020-10-21 Immutep S.A.S. Anti-lag-3 antibodies
IL257858B (en) 2015-10-02 2022-09-01 Hoffmann La Roche Antibodies against pd1 and methods of their use
WO2017055314A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Bispecific anti-cd19xcd3 t cell activating antigen binding molecules
CA3000045C (en) 2015-10-02 2024-01-02 F. Hoffmann-La Roche Ag Anti-human cd19 antibodies with high affinity
CN108139394B (zh) 2015-10-02 2020-10-30 豪夫迈·罗氏有限公司 用于确定同时结合的基于细胞的fret测定法
WO2017055404A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Bispecific antibodies specific for pd1 and tim3
EP3150636A1 (en) 2015-10-02 2017-04-05 F. Hoffmann-La Roche AG Tetravalent multispecific antibodies
JP7074665B2 (ja) 2015-10-07 2022-05-24 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 共刺激ｔｎｆ受容体に対する四価の二重特異性抗体発明の分野
BR112018009009A8 (pt) 2015-11-03 2019-02-26 Hoffmann La Roche terapia combinada de um inibidor de formação de capsídeo hbv e um interferon
JP7003036B2 (ja) 2015-12-02 2022-02-04 エスティーキューブ，インコーポレイテッド グリコシル化ｐｄ－１に対して特異的な抗体およびその使用方法
JP6872550B2 (ja) 2015-12-10 2021-05-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 架橋されたピペリジン誘導体
EP3436475A1 (en) 2016-03-29 2019-02-06 STCube & Co., Inc. Methods for selecting antibodies that specifically bind glycosylated immune checkpoint proteins
EP3243836A1 (en) 2016-05-11 2017-11-15 F. Hoffmann-La Roche AG C-terminally fused tnf family ligand trimer-containing antigen binding molecules
WO2017194442A1 (en) 2016-05-11 2017-11-16 F. Hoffmann-La Roche Ag Antigen binding molecules comprising a tnf family ligand trimer and a tenascin binding moiety
EP3243832A1 (en) 2016-05-13 2017-11-15 F. Hoffmann-La Roche AG Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety
CN106519034B (zh) * 2016-12-22 2020-09-18 鲁南制药集团股份有限公司 抗pd-1抗体及其用途
EP3606947B1 (en) 2017-04-03 2022-12-21 F. Hoffmann-La Roche AG Immunoconjugates of il-2 with an anti-pd-1 and tim-3 bispecific antibody
CN117003887A (zh) 2017-04-03 2023-11-07 豪夫迈·罗氏有限公司 抗pd-1抗体与突变体il-2或与il-15的免疫缀合物
CA3057558A1 (en) 2017-04-05 2018-10-11 Boehringer Ingelheim International Gmbh Anticancer combination therapy
MA49038A (fr) 2017-04-05 2020-02-12 Hoffmann La Roche Anticorps bispécifiques se liant particulièrement à pd1 et lag3
HUE060019T2 (hu) 2017-04-05 2023-01-28 Hoffmann La Roche Anti-LAG3 antitestek
EA201992350A1 (ru) 2017-04-05 2020-03-23 Симфоген А/С Комбинированные лекарственные средства, нацеленные на pd-1, tim-3 и lag-3
WO2018189220A1 (en) 2017-04-13 2018-10-18 F. Hoffmann-La Roche Ag An interleukin-2 immunoconjugate, a cd40 agonist, and optionally a pd-1 axis binding antagonist for use in methods of treating cancer
CN111315781A (zh) 2017-11-01 2020-06-19 豪夫迈·罗氏有限公司 用靶向性ox40激动剂的组合疗法
AU2018357923A1 (en) 2017-11-01 2020-03-05 F. Hoffmann-La Roche Ag Bispecific 2+1 contorsbodies
SG11202112491WA (en) 2019-07-31 2021-12-30 Hoffmann La Roche Antibodies binding to gprc5d
US20230192795A1 (en) 2020-04-15 2023-06-22 Hoffmann-La Roche Inc. Immunoconjugates
PE20231361A1 (es) 2020-06-23 2023-09-05 Hoffmann La Roche Moleculas agonistas de union al antigeno cd28 que se dirigen a her2
EP4172203A1 (en) 2020-06-25 2023-05-03 F. Hoffmann-La Roche AG Anti-cd3/anti-cd28 bispecific antigen binding molecules
US11865082B2 (en) 2020-09-09 2024-01-09 Hoffmann-La Roche Inc. Combination therapy of PD-1-targeted IL-2 variant immunocytokines and antibodies against human PD-L1
EP4274658A1 (en) 2021-01-06 2023-11-15 F. Hoffmann-La Roche AG Combination therapy employing a pd1-lag3 bispecific antibody and a cd20 t cell bispecific antibody
WO2022148853A1 (en) 2021-01-11 2022-07-14 F. Hoffmann-La Roche Ag Immunoconjugates
EP4304724A1 (en) 2021-03-09 2024-01-17 F. Hoffmann-La Roche AG Combination therapy of pd-1-targeted il-2 variant immunoconjugate and anti-tyrp1/anti-cd3 bispecific antibodies
CA3209640A1 (en) 2021-03-09 2022-09-15 F. Hoffmann-La Roche Ag Combination therapy of pd-1-targeted il-2 variant immunoconjugates and fap/4-1bb binding molecules

Also Published As

Publication number Publication date
CA3053357A1 (en) 2018-10-11
IL269395B1 (en) 2024-09-01
US12023368B2 (en) 2024-07-02
WO2018184964A1 (en) 2018-10-11
AR111400A1 (es) 2019-07-10
US20180326010A1 (en) 2018-11-15
KR20210124518A (ko) 2021-10-14
JP2024045143A (ja) 2024-04-02
AU2018247765A1 (en) 2019-08-22
EP3606946A1 (en) 2020-02-12
MX2023003397A (es) 2023-03-31
HRP20221254T1 (hr) 2022-12-23
CN110392692A (zh) 2019-10-29
CN110392692B (zh) 2023-07-21
RS63663B1 (sr) 2022-11-30
PH12019502273A1 (en) 2020-12-07
CL2019002346A1 (es) 2020-01-10
EP4201953A1 (en) 2023-06-28
CO2019009354A2 (es) 2019-09-09
RU2019134338A (ru) 2021-05-05
IL269395A (en) 2019-11-28
CR20190426A (es) 2019-11-01
US20230134606A1 (en) 2023-05-04
DK3606946T3 (da) 2022-10-24
PT3606946T (pt) 2022-10-17
US11413331B2 (en) 2022-08-16
MX2019011770A (es) 2020-01-09
MA49033A (fr) 2020-02-12
PE20191494A1 (es) 2019-10-21
UA125700C2 (uk) 2022-05-18
EP3606946B1 (en) 2022-08-24
AU2018247765B2 (en) 2023-11-23
TW201900220A (zh) 2019-01-01
JP7426825B2 (ja) 2024-02-02
JP2022062001A (ja) 2022-04-19
KR20190121816A (ko) 2019-10-28
PL3606946T3 (pl) 2022-11-28
HUE059885T2 (hu) 2023-01-28
RU2761377C2 (ru) 2021-12-07
SG11201909205YA (en) 2019-11-28
CN117003887A (zh) 2023-11-07
MY201482A (en) 2024-02-26
BR112019017329A2 (pt) 2020-04-14
ES2928718T3 (es) 2022-11-22
KR102461885B1 (ko) 2022-11-03
MA49033B1 (fr) 2022-10-31
LT3606946T (lt) 2022-10-25
RU2019134338A3 (es) 2021-05-05
JP2020515275A (ja) 2020-05-28
TWI800506B (zh) 2023-05-01
ZA201905517B (en) 2021-05-26

Similar Documents

Publication Publication Date Title
AR126987A2 (es) Inmunoconjugados
AR127371A2 (es) Receptores quiméricos de flt3 y métodos para usarlos
AR111203A1 (es) Inmunoconjugados
HRP20191409T1 (hr) Postupci i sredstva za proizvodnju heterodimernih ig-sličnih molekula
AR126242A2 (es) Tratamiento del cáncer utilizando receptores de antígenos quiméricos
AR124240A2 (es) Un anticuerpo biespecífico anti-vegf / anti-ang-2, ácido nucleico, vector de expresión, célula huésped y un método de preparación del anticuerpo
AR077973A1 (es) Anticuerpos anti-cdcp1 humanizados
AR109659A2 (es) Anticuerpos inhibidores de la dimerización del c-met y usos de los mismos
BR112019005316A2 (pt) anticorpos monoclonais para morte programada 1 (pd-1)
AR094141A1 (es) Composiciones y metodos para proteinas de accion prolongada
EA202092735A1 (ru) Антагонизирующее cd73 антитело
PE20181322A1 (es) Anticuerpo anti-pd1 y sus metodos de uso
PE20232039A1 (es) Mutantes de proteina f de rsv
AR097405A1 (es) Diacuerpos monovalentes biespecíficos que son capaces de unirse a cd123 y cd3 y usos de los mismos
AR086360A1 (es) Polipeptidos anticuerpos que antagonizan cd40
MX2020005127A (es) Plataforma de presentacion en endosporas basadas en paenibacillus, productos y metodos relacionados.
MX2016011934A (es) Inmunoglobulina hibrida conteniendo un enlace no-peptidilico.
AR101753A1 (es) COMPUESTO DE OBJETIVO A IL-23A Y TNF-a Y USO DEL MISMO
AR101202A1 (es) Anticuerpo anti-tie2 humana
BR112022006233A2 (pt) Composições e métodos para síntese in vivo de polipeptídeos não naturais
BR112016014913A8 (pt) anticorpo, ou um fragmento de ligação ao antígeno do mesmo, conjugado, ácido nucléico, vetor, célula hospedeira, composição farmacêutica, método de preparo de uma cadeia leve de um anticorpo ou fragmento de ligação ao antígeno e método de preparo de um conjugado
SA520412282B1 (ar) خلية مؤهلة مناعيًا تعبر عن جزيء سطح خلية يتعرف على وجه التحديد على ccl19 il-7 ميزوثيلين بشري،
AR111963A1 (es) Método y moléculas
AR101735A1 (es) Anticuerpo terapéutico anti-bdnf (factor neurotrófico derivado del cerebro)
CO2022015202A2 (es) Moléculas de unión al antígeno multiespecíficas dirigidas a claudina-6 y sus usos